Pyxis Oncology, Inc.
PYXS Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$1.68
KIRA · Stoqly’s AI analyst, in plain words
- Pyxis Oncology, Inc. had $13.9M of revenue in fiscal 2025, down 14.2% on the year before.
- Its operating margin was −609.2%, down 55.1 pts: of every 100 in sales, about −609 is left after running the business.
- Pyxis Oncology, Inc. lost $79.6M in fiscal 2025.
- Free cash flow was −$63.5M in fiscal 2025, −458.3% of revenue.
Market cap
$108M
P/E
—
Revenue
$13.9M
Net income
−$79.6M
Free cash flow
−$63.5M
Operating margin
−609.2%
Pyxis Oncology, Inc. in 30 seconds · fiscal 2025
Are sales growing?
−14.2%
No. Sales fell 14.2% last year.
Does it make a profit?
−574.5%
No. It lost money last year.
Does profit turn into cash?
−458.3%
No. It spent more cash than it brought in.
How healthy are the accounts?
2 / 8
Weak. It passes 2 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Pyxis Oncology, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 23, 2026
- Legal name
- Pyxis Oncology, Inc.
- CIK
- 0001782223
Pyxis Oncology, Inc. · PYXS
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | — | — | — | $16.1M | $13.9M |
| Revenue growth | — | — | — | — | −14.2% |
| Gross margin | — | — | — | 97.1% | 82.8% |
| Operating margin | — | — | — | −554.1% | −609.2% |
| Net income | −$76.0M | −$121M | −$73.8M | −$77.3M | −$79.6M |
| Net margin | — | — | — | −478.9% | −574.5% |
| Diluted EPS | −$8.95 | −$3.65 | −$1.85 | −$1.32 | −$1.28 |
| Cash | |||||
| Cash from operations | −$35.3M | −$89.3M | −$70.7M | −$57.7M | −$63.5M |
| Capital expenditure | $0.5M | $6.4M | $6.7M | $0.2M | $0.0M |
| Free cash flow | −$35.9M | −$95.7M | −$77.4M | −$57.9M | −$63.5M |
| FCF margin | — | — | — | −358.7% | −458.3% |
| Share count change | 724.1% | 288.9% | 20.8% | 46.5% | 6.3% |
| Debt and strength | |||||
| Cash and short-term investments | $275M | $179M | $119M | $127M | $66.9M |
| Shareholders' equity | $261M | $161M | $126M | $121M | $53.4M |
| Current ratio | 14.9x | 5.9x | 4.8x | 7.5x | 3.4x |
| Returns and quality | |||||
| Return on equity | −61.9% | −57.2% | −51.5% | −62.8% | −91.4% |
| Return on tangible equity | −29.1% | −75.1% | −72.8% | −65.5% | −149.1% |
| Piotroski F-score | — | — | — | — | 2 |
| Altman Z'' | 18.0 | 0.9 | −2.1 | −3.1 | −16.9 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.1M
1 insider
Of sales under plans
100%
$0.1M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Pyxis Oncology, Inc. · PYXS
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $1.68 a share, the company is worth $108M.
Source: SEC EDGAR XBRL filings (CIK 0001782223). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.